Canadian FOP Network
  • Home
  • Our Role & Impact
    • About the Network
    • Volunteer Board & Officers
    • Our Stories >
      • Adam
      • Brooke
      • Kathleen
      • Miranda
      • Valerie
    • How do We Get a Cure >
      • Research
      • Clementia Pharmaceutical
      • Regeneron Pharmaceuticals
    • Financial Information
  • Understanding FOP
    • Diagnosis & Symptoms >
      • Prognosis
    • Life with FOP
    • Research / Clinical Trials >
      • Our Expert Partner IFOPA
  • Get Involved
    • Become a Member
    • Volunteer
    • Donate to Fund a Cure
    • Host a Fundraiser
  • Multi-Media
  • News & Events
  • Brooke Connell Golf Tournament
  • Important Contacts
  • Links to Resources
  • Our Friends Around the World
  • Blog
  • Product

Understanding FOP

FOP is a progressive and debilitating genetic disorder characterized by heterotopic ossification (HO).  The defining sign present at birth is a malformation of the great toes.  In early childhood, children develop soft tissue swellings that transform into bone.  Development of such lesions is exacerbated by trauma, and surgical intervention leads to dramatic and explosive new bone growth.  The median survival of FOP patients is approximately 45 years, and death often results from complications of thoracic insufficiency syndrome. 

FOP is an extremely rare condition affecting 1 in 2,000,000 people. In addition, overactivity of the BMP-2 receptor causes heterotopic ossification as a result of trauma.  Trauma induced HO outside of FOP can be seen in soldiers who afterseverely debilitating complication that is increasing significantly in prevalence.  It is estimated that 64% of soldiers with blast injuries to the extremities develop HO, compromising functional mobility and prosthesis use.

CFOPN is a member of:

Picture

CFOPN, 101 Brixham Cr, London, ON, N6K 1K9
Ph#: 226-377-1282
Registered Charity #834338691RR0001
Proudly powered by Weebly